444 related articles for article (PubMed ID: 31206316)
1. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.
Ricciuti B; Dahlberg SE; Adeni A; Sholl LM; Nishino M; Awad MM
J Clin Oncol; 2019 Aug; 37(22):1927-1934. PubMed ID: 31206316
[TBL] [Abstract][Full Text] [Related]
2. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
Fucà G; Galli G; Poggi M; Lo Russo G; Proto C; Imbimbo M; Vitali M; Ganzinelli M; Lanti C; Molino G; Stangoni F; Zilembo N; de Braud F; Garassino MC; Signorelli D
Target Oncol; 2018 Dec; 13(6):795-800. PubMed ID: 30306460
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153
[TBL] [Abstract][Full Text] [Related]
4. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
Arbour KC; Mezquita L; Long N; Rizvi H; Auclin E; Ni A; Martínez-Bernal G; Ferrara R; Lai WV; Hendriks LEL; Sabari JK; Caramella C; Plodkowski AJ; Halpenny D; Chaft JE; Planchard D; Riely GJ; Besse B; Hellmann MD
J Clin Oncol; 2018 Oct; 36(28):2872-2878. PubMed ID: 30125216
[TBL] [Abstract][Full Text] [Related]
5. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
Maymani H; Hess K; Groisberg R; Hong DS; Naing A; Piha-Paul S; Janku F; Fu S; Tsimberidou AM; Pant S; Karp D; Liu S; Sun M; Heymach J; Simon G; Meric-Bernstam F; Subbiah V
Lung Cancer; 2018 Jun; 120():137-141. PubMed ID: 29748008
[TBL] [Abstract][Full Text] [Related]
6. Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Αfter Definitive Chemoradiotherapy.
Morimoto M; Nishino K; Wada K; Imamura F; Konishi K; Kuhara H; Tamiya M; Inoue T; Kunimasa K; Kimura M; Hirata T; Kanayama N; Toratani M; Kawachi H; Ohira K; Nakanishi E; Ohira S; Sagawa T; Miyazaki M; Matsunaga T; Kumagai T; Teshima T
Anticancer Res; 2020 Dec; 40(12):6957-6970. PubMed ID: 33288590
[TBL] [Abstract][Full Text] [Related]
7. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
8. Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.
Brule SY; Al-Baimani K; Jonker H; Zhang T; Nicholas G; Goss G; Laurie SA; Wheatley-Price P
Lung Cancer; 2016 Jul; 97():15-21. PubMed ID: 27237022
[TBL] [Abstract][Full Text] [Related]
9. Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer.
Kim HJ; Kim YJ; Seo MD; Yi HG; Lee SH; Lee SM; Kim DW; Yang SC; Lee CT; Lee JS; Kim YW; Heo DS
Lung Cancer; 2009 Aug; 65(2):242-6. PubMed ID: 19147252
[TBL] [Abstract][Full Text] [Related]
10. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.
Owen DH; Wei L; Bertino EM; Edd T; Villalona-Calero MA; He K; Shields PG; Carbone DP; Otterson GA
Clin Lung Cancer; 2018 Nov; 19(6):e893-e900. PubMed ID: 30197259
[TBL] [Abstract][Full Text] [Related]
11. Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer.
Provencio M; Carcereny E; Artal Á
Clin Transl Oncol; 2019 Nov; 21(11):1464-1471. PubMed ID: 30903517
[TBL] [Abstract][Full Text] [Related]
12. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
13. Evaluating for Correlations between Specific Metabolites in Patients Receiving First-Line or Second-Line Immunotherapy for Metastatic or Recurrent NSCLC: An Exploratory Study Based on Two Cohorts.
Xu Y; Ding K; Peng Z; Ding L; Li H; Fan Y
Mol Cancer Ther; 2024 May; 23(5):733-742. PubMed ID: 38346938
[TBL] [Abstract][Full Text] [Related]
14. Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer.
Li H; Verma V; Brooks ED; Feng L; Zhang T; Welsh JW; Lin SH; Gomez D; Gandhi S; Heymach JV; Chang JY
Clin Lung Cancer; 2019 Jul; 20(4):e480-e488. PubMed ID: 31078421
[TBL] [Abstract][Full Text] [Related]
15. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
[TBL] [Abstract][Full Text] [Related]
16. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
Singh C; Qian JM; Yu JB; Chiang VL
J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
[TBL] [Abstract][Full Text] [Related]
17. [Exploration of the treatment model for patients with advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease based on real-world data].
Wang F; Xie XH; Lin XQ; Qin YY; Xie ZH; Zhang JX; Ouyang M; Zhou CZ
Zhonghua Jie He He Hu Xi Za Zhi; 2020 May; 43(5):450-454. PubMed ID: 32450634
[No Abstract] [Full Text] [Related]
18. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
19. Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study.
Nelli F; Virtuoso A; Berrios JRG; Giannarelli D; Fabbri A; Marrucci E; Ruggeri EM
Cancer Chemother Pharmacol; 2022 Apr; 89(4):529-537. PubMed ID: 35301584
[TBL] [Abstract][Full Text] [Related]
20. TKIs beyond immunotherapy predict improved survival in advanced HCC.
Armstrong S; Roy T; Singh B; Kulasekaran M; Shaukat F; Geng X; Wang H; Prins P; Jha RC; Hartley ML; He AR
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2559-2574. PubMed ID: 35773429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
